These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34936164)

  • 1. Predicting long-term trends in inflammatory neuropathy outcome measures using latent class modelling.
    Keh RYS; Selby DA; Jones S; Gosal D; Lavin T; Lilleker JB; Carr AS; Lunn MP
    J Peripher Nerv Syst; 2022 Mar; 27(1):84-93. PubMed ID: 34936164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dramatic clinical response to ultra-high dose IVIg in otherwise treatment resistant inflammatory neuropathies.
    Kapoor M; Reilly MM; Manji H; Lunn MP; Aisling S ; Carr
    Int J Neurosci; 2022 Apr; 132(4):352-361. PubMed ID: 32842835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post-hoc analysis of the immunoglobulin overtreatment in CIDP trial.
    van Veen R; Wieske L; Lucke I; Adrichem ME; Merkies ISJ; van Schaik IN; Eftimov F
    J Peripher Nerv Syst; 2022 Jun; 27(2):144-158. PubMed ID: 35507446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance.
    Merkies IS; van Nes SI; Hanna K; Hughes RA; Deng C
    J Neurol Neurosurg Psychiatry; 2010 Nov; 81(11):1194-9. PubMed ID: 20647554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An approach to assessing immunoglobulin dependence in chronic inflammatory demyelinating inflammatory polyneuropathy.
    Kapoor M; Compton L; Rossor A; Hutton E; Manji H; Lunn M; Reilly M; Carr A
    J Peripher Nerv Syst; 2021 Dec; 26(4):461-468. PubMed ID: 34637194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness.
    Draak TH; Vanhoutte EK; van Nes SI; Gorson KC; Van der Pol WL; Notermans NC; Nobile-Orazio E; Léger JM; Van den Bergh PY; Lauria G; Bril V; Katzberg H; Lunn MP; Pouget J; van der Kooi AJ; Hahn AF; Doorn PA; Cornblath DR; van den Berg LH; Faber CG; Merkies IS;
    Neurology; 2014 Dec; 83(23):2124-32. PubMed ID: 25378677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Tedeschi G
    Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impairment measures versus inflammatory RODS in GBS and CIDP: a responsiveness comparison.
    Vanhoutte EK; Draak TH; Gorson KC; van Nes SI; Hoeijmakers JG; Van der Pol WL; Notermans NC; Lewis RA; Nobile-Orazio E; Léger JM; Van den Bergh PY; Lauria G; Bril V; Katzberg H; Lunn MP; Pouget J; van der Kooi AJ; Hahn AF; van Doorn PA; Cornblath DR; van den Berg LH; Faber CG; Merkies IS;
    J Peripher Nerv Syst; 2015 Sep; 20(3):289-95. PubMed ID: 26114893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Home monitoring of maintenance intravenous immunoglobulin therapy in patients with chronic inflammatory neuropathy.
    Doneddu PE; Mandia D; Gentile F; Gallia F; Liberatore G; Terenghi F; Ruiz M; Nobile-Orazio E
    J Peripher Nerv Syst; 2020 Sep; 25(3):238-246. PubMed ID: 32470190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment timing and choice of outcome measure in determining treatment response in chronic inflammatory demyelinating polyneuropathy: A post hoc analysis of the PRISM trial.
    Rajabally YA; Ouaja R; Kasiborski F; Pujol S; Nobile-Orazio E
    Muscle Nerve; 2022 Nov; 66(5):562-567. PubMed ID: 36057106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy.
    Klehmet J; Beutner S; Hoffmann S; Dornauer M; Paul F; Reilmann R; Brandt AU; Meisel A
    BMC Neurol; 2019 Jun; 19(1):118. PubMed ID: 31176377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes.
    Alabdali M; Abraham A; Alsulaiman A; Breiner A; Barnett C; Katzberg HD; Lovblom LE; Perkins BA; Bril V
    J Neurol Sci; 2017 Jan; 372():223-227. PubMed ID: 28017218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome measures in pediatric chronic inflammatory demyelinating polyradiculoneuropathy.
    Guttikonda A; Ahmad G; Goyal P; Xiang Y; Johnson LM; Gillespie S; Carvell KT; Butera R; Verma S
    Muscle Nerve; 2024 May; 69(5):580-587. PubMed ID: 38436500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study.
    Vanhoutte EK; Latov N; Deng C; Hanna K; Hughes RA; Bril V; Dalakas MC; Donofrio P; van Doorn PA; Hartung HP; Merkies IS
    Eur J Neurol; 2013 May; 20(5):748-55. PubMed ID: 22891893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta-analysis.
    Racosta JM; Sposato LA; Kimpinski K
    Muscle Nerve; 2017 Jun; 55(6):802-809. PubMed ID: 27649063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An international multicenter efficacy and safety study of IqYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study.
    Nobile-Orazio E; Pujol S; Kasiborski F; Ouaja R; Corte GD; Bonek R; Cocito D; Schenone A
    J Peripher Nerv Syst; 2020 Dec; 25(4):356-365. PubMed ID: 32808406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the Serbian version of inflammatory Rasch-built overall disability scale in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
    Peric S; Bozovic I; Pruppers MHJ; Bjelica B; Stevic Z; Faber CG; Merkies ISJ; Basta I
    J Peripher Nerv Syst; 2019 Sep; 24(3):260-267. PubMed ID: 31397933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
    Merkies ISJ; van Schaik IN; Léger JM; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Durn BL; Cornblath DR; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Tackenberg B; Mielke O;
    J Peripher Nerv Syst; 2019 Mar; 24(1):48-55. PubMed ID: 30672091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of immune-mediated inflammatory neuropathies.
    Hadden RD; Hughes RA
    Curr Opin Neurol; 1999 Oct; 12(5):573-9. PubMed ID: 10590894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
    Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
    Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.